- Home
- LNTH vs LAZ Comparison
LNTH vs LAZ Comparison
Compare LNTH & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNTH | LAZ |
|---|---|---|
| Founded | 1956 | 1848 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.3B |
| IPO Year | 2014 | 2004 |
Fundamental Metrics
Financial Performance| Metric | LNTH | LAZ |
|---|---|---|
| Price | $79.57 | $40.29 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 8 |
| Target Price | ★ $83.20 | $55.38 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-25-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.92% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.41 | 2.17 |
| Revenue | $343,374,000.00 | ★ $3,186,466,000.00 |
| Revenue This Year | N/A | $15.81 |
| Revenue Next Year | $13.47 | $12.49 |
| P/E Ratio | $23.56 | ★ $18.69 |
| Revenue Growth | ★ 3.62 | 1.48 |
| 52 Week Low | $47.27 | $31.97 |
| 52 Week High | $108.86 | $58.75 |
Technical Indicators
Market Signals| Indicator | LNTH | LAZ |
|---|---|---|
| Relative Strength Index (RSI) | 60.94 | 25.56 |
| Support Level | $77.38 | N/A |
| Resistance Level | $83.53 | $52.92 |
| Average True Range (ATR) | 3.71 | 2.35 |
| MACD | 0.28 | -0.98 |
| Stochastic Oscillator | 60.42 | 5.03 |
Price Performance
Historical ComparisonAbout LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About LAZ Lazard Inc.
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.